Valuation: Simulations Plus

Market Cap 37Cr 33Cr 31Cr 28Cr 52Cr 3.53TCr 53Cr 365.59Cr 146.76Cr 1.86TCr 139.66Cr 136.69Cr 5.86TCr P/E 2024
74x
P/E 2025 -4.4x
Enterprise Value 34Cr 30Cr 28Cr 25Cr 47Cr 3.23TCr 48Cr 334.41Cr 134.24Cr 1.7TCr 127.75Cr 125.03Cr 5.36TCr EV / Sales 2024
10.1x
EV / Sales 2025 3.2x
Free-Float
99.98%
Yield 2024
0.66%
Yield 2025 -
Current month+0.38%
1 month+0.38%
3 months+1.09%
6 months+30.56%
Current year+1.48%
1 month 18.49
Extreme 18.49
18.5
Current year 11.09
Extreme 11.09
21.01
1 year 11.09
Extreme 11.09
21.01
3 years 11.09
Extreme 11.09
51.22
5 years 11.09
Extreme 11.09
67.59
10 years 8.3
Extreme 8.3
90.92
Manager TitleAgeSince
Chief Executive Officer 67 26/06/2018
Director of Finance/CFO 63 01/12/2020
Chief Tech/Sci/R&D Officer - -
Date Insider Type Main position Quantity % Market Cap. Importance
06/10/26 Issuer sale

Chairman

-23,547 0.1169%
06/10/26 Issuer sale

Chief Financial Officer

-1,09,600 0.5440%
06/10/26 Issuer sale

Founder

-32,07,131 15.9190%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%+7.81%-45.40% 37Cr
-1.72%+3.44%+25.31%+60.56% 26TCr
-2.00%+0.75%+7.99%+25.46% 16TCr
-3.73%-4.48%-18.49%+67.13% 15TCr
-1.66%-8.12%-58.26%-16.12% 6.08TCr
-2.57%+3.30%+10.22%+47.55% 5.3TCr
0.00%+2.46%-11.97%-6.29% 5.33TCr
-3.47%+1.04%+21.98%+72.85% 4.93TCr
+0.84%-3.12%+9.80%+64.47% 5.07TCr
-3.61%+1.99%+34.94%+95.49% 4.55TCr
Average -1.79%-0.26%+2.93%+36.57% 8.84TCr
Weighted average by Cap. -2.10%+0.15%+5.19%+47.75%

Financials

2024 2025
Net sales 7Cr 6.27Cr 5.77Cr 5.23Cr 9.77Cr 664.78Cr 9.95Cr 69Cr 28Cr 349.69Cr 26Cr 26Cr 1.1TCr 7.92Cr 7.09Cr 6.52Cr 5.91Cr 11Cr 751.81Cr 11Cr 78Cr 31Cr 395.47Cr 30Cr 29Cr 1.25TCr
Net income 99.54L 89.15L 82L 74.3L 1.39Cr 95Cr 1.41Cr 9.78Cr 3.93Cr 50Cr 3.74Cr 3.66Cr 156.79Cr -6.47Cr -5.8Cr -5.33Cr -4.83Cr -9.03Cr -614.5Cr -9.2Cr -64Cr -26Cr -323.25Cr -24Cr -24Cr -1.02TCr
Net Debt -1.92Cr -1.72Cr -1.59Cr -1.44Cr -2.69Cr -182.77Cr -2.74Cr -19Cr -7.59Cr -96Cr -7.22Cr -7.07Cr -303.2Cr -3.17Cr -2.84Cr -2.61Cr -2.37Cr -4.43Cr -301.35Cr -4.51Cr -31Cr -13Cr -158.52Cr -12Cr -12Cr -499.9Cr
Projected Income Statement - Annual - Simulations Plus
Logo Simulations Plus
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Employees
213
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Simulations Plus